Revolution Medicines

Revolution Medicines is a clinical-stage precision oncology company headquartered in Redwood City, California, developing targeted therapies for RAS-addicted cancers. Its pipeline centers on RAS(ON) inhibitors — including daraxonrasib (RMC-6236), zoldonrasib (RMC-9805), and elironrasib (RMC-6291) — designed to directly target the active, GTP-bound (ON) state of oncogenic RAS proteins across mutations such as KRAS G12X. The company pairs structure-based drug discovery with clinical development to pursue treatments for pancreatic, lung, colorectal, and other RAS-driven tumors. Revolution Medicines is a publicly traded corporate entity (Nasdaq: RVMD) and does not currently expose a public developer API surface; this profile captures its identity and domain-security posture for the API Evangelist network.

Revolution Medicines is profiled on the APIs.io network. Tagged areas include Company, Life Sciences, Oncology, Biotechnology, and Pharmaceuticals.

🌐 Visit website 📡 Source on GitHub
6.2/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-08-20 · rubric v0.12.0
0 APIs
CompanyLife SciencesOncologyBiotechnologyPharmaceuticalsCancerDrug DiscoveryRAS

Kin Score

Kin Score Kin Score How this is scored →
scored 2026-08-20 · rubric v0.12.0
Composite quality — 6.2/100 · minimal
Contract Quality 0.0 / 21
Developer Ergonomics 0.0 / 17
Access Clarity 1.8 / 17
Operational Transparency 0.0 / 11
Contract Governance 0.0 / 10
Discoverability 4.3 / 9
Regulatory Posture 1.9 / 15
Agent readiness — 0/100 · human only
Machine-Readable Contract 0 / 18
Agentic Access Contract 0 / 10
Documented Reversibility 0 / 6
MCP Server 0 / 12
Machine-Readable Auth 0 / 10
Idempotency 0 / 9
Stable Error Semantics 0 / 8
Request/Response Examples 0 / 7
Rate-Limit Signaling 0 / 7
Typed Event Surface 0 / 6
Agent Skills 0 / 5
Well-Known Catalog 0 / 4
Consent & Bot Identity 0 / 3
A2A Agent Card 0 / 8
Dry-Run / Simulate Mode 0 / 4
Regulatory Posture applies to this provider. Its tags matched the Health regime, so Regulatory Posture carries 15 points of the composite. If this regime is wrong for your business, say so on your provider repo — the applicability map is public and we will correct it.
The six quality facets above are damped to 85 points between them, because the conditional facet above carries the other 15. That is why each facet's contribution is shown against a damped maximum: raising a quality facet moves the composite by 85% of its nominal weight, not 100%. The full arithmetic is at apis.io/rating/.
Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/revolution-medicines: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Security Posture 1

Authentication, domain security, vulnerability disclosure, and trust-center signals.

Revolution Medicines Domain Security

TLSv1.3 · DMARC

SECURITY

Resources

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity
DomainSecurity

Commercial 1

Pricing, plans, and the legal terms of use

PrivacyPolicy
PrivacyPolicy

Company 1

The organization behind the API

Website
Website

Source (apis.yml)

apis.yml Raw ↑ 
aid: revolution-medicines
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/revolution-medicines.png
name: Revolution Medicines
description: 'Revolution Medicines is a clinical-stage precision oncology company headquartered in Redwood City, California,
  developing targeted therapies for RAS-addicted cancers. Its pipeline centers on RAS(ON) inhibitors — including daraxonrasib
  (RMC-6236), zoldonrasib (RMC-9805), and elironrasib (RMC-6291) — designed to directly target the active, GTP-bound (ON)
  state of oncogenic RAS proteins across mutations such as KRAS G12X. The company pairs structure-based drug discovery with
  clinical development to pursue treatments for pancreatic, lung, colorectal, and other RAS-driven tumors. Revolution Medicines
  is a publicly traded corporate entity (Nasdaq: RVMD) and does not currently expose a public developer API surface; this
  profile captures its identity and domain-security posture for the API Evangelist network.'
url: https://raw.githubusercontent.com/api-evangelist/revolution-medicines/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- gv
x-tier: stub
x-tier-reason: portfolio-lead
specificationVersion: '0.23'
created: '2026-07-17'
modified: '2026-07-20'
tags:
- Company
- Life Sciences
- Oncology
- Biotechnology
- Pharmaceuticals
- Cancer
- Drug Discovery
- RAS
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: Website
  url: https://www.revmed.com
- type: PrivacyPolicy
  url: https://www.revmed.com/privacy-policy/
- type: DomainSecurity
  url: security/revolution-medicines-domain-security.yml
x-enrichment:
  date: '2026-07-20'
  status: minimal
  artifacts_added: 1
  pass: local-v1